Introduction
============

Acute kidney injury (AKI) is a common complication in cancer patients due to exposure to contrast media, cytotoxic agents, surgical treatment, antibiotics and nonsteroidal anti-inflammatory drugs. In addition, critically ill cancer patients are at increased risk for AKI associated with volume depletion and sepsis \[[@ref1]\].

Studies including critically ill patients with hematologic and solid neoplasms have identified an incidence of AKI ranging from 22 to 100%, using the criteria proposed by the Acute Kidney Injury Network and the organisation Kidney disease: Improving Global Outcomes (KDIGO), additionally the presence of AKI is associated with higher mortality \[[@ref2]--[@ref4]\].

Serum creatinine (SCr) and urinary output (UO) are traditional markers of AKI; however, decreased muscle mass, inflammation, volume expansion or medications can alter SCr production, limiting its sensitivity. Therefore, biomarkers that are more sensitive are under investigation \[[@ref1]\].

Plasmatic neutrophil gelatinase-associated lipocalin (NGAL) has demonstrated good predictive performance in children \[[@ref5]\]. Nevertheless, in adult critically ill patients, the results are heterogeneous, with an area under the curve (AUC) of less than 0.7 in recent studies \[[@ref6], [@ref7]\].

Most studies investigating AKI biomarkers in cancer patients focus on early detection of nephrotoxicity mediated by anticancer drugs \[[@ref8], [@ref9]\]. However, in critically ill cancer patients, inflammatory biomarkers, such as NGAL, may be influenced by numerous sources of inflammation and do not reflect tubular damage. Therefore, we aim to explore the predisposing factors of AKI and the performance of NGAL in a population of critically ill cancer patients.

Methods
=======

We performed a prospective observational study from April 2014 to July 2015, at the Instituto Nacional de Cancerología, a tertiary care cancer centre. The institutional ethics committee approved this study (Prot. No. 014/011/SCI/CEI/860). Written informed consent was obtained from all participants or primary caregivers. We included 96 critically ill cancer patients at the time of admission to the ICU. We excluded patients who had an ICU stay of ≤24 hours or patients under 18 years, with known chronic kidney disease (CKD), long-term or acute renal replacement therapy (RRT), previous kidney transplantation and renal or urologic cancer ([Figure 1](#figure1){ref-type="fig"}). ICU readmissions were not considered. We estimated glomerular filtration rate (GFR) using the CKD Epidemiology Collaboration equation, CKD was defined as GFR \< 60 mL/min/1.73m^2^ for at least 3 months prior to admission \[[@ref10]\].

Researchers also recorded demographic characteristics, comorbidities, cancer status, sepsis, mechanical ventilation, acute physiology and chronic health evaluation (APACHE II) \[[@ref11]\], sequential organ failure assessment (SOFA) \[[@ref12]\] score and laboratory values. In addition, registered days with mechanical ventilation, days with norepinephrine ICU stay and death at 180 days were recorded.

Acute kidney injury criteria
============================

We defined AKI according to KDIGO Clinical Practice Guidelines. Stage 1 AKI was defined as 0.3 mg/dL SCr elevation above baseline within 48 hours, and/or UO less than 0.5 mL/kg/h for 6--12 hours. Stage 2 AKI was defined as SCr with a 2--2.9-fold increase compared with the baseline value, and/or UO less than 0.5 mL/kg/h for 12--24 hours. Stage 3 AKI was defined as SCr greater than three-fold the baseline value, UO less than 0.3 mL/kg/h for greater than 24 hours, anuria for greater than 12 hours or RRT requirement \[[@ref13]\].

We considered baseline creatinine as the lowest value in the 3 months preceding hospitalisation. In patients without historical values, the baseline was calculated by estimating the eGFR at 75 mL/min/1.73 m^2^ \[[@ref13]\].

Plasma collection and processing
================================

Plasma concentrations of NGAL were measured at 24 hours and 48 hours during the stay in the ICU. Plasma samples were freshly collected in tubes with heparin, placed on ice and centrifuged for 15 minutes. The supernatant was stored at −20°C until assayed. Plasma samples were diluted 20 times, with a calibrator included in the commercial kit *Human Lipocalin kit-1/NGAL (R&D Systems)*. The conjugated sample remained stored at 2°C−8°C. The other reagents were left at room temperature before use. The washing buffer was incubated at room temperature and gently stirred until the crystals dissolved. We diluted 20 mL with deionised water to prepare 500 mL of washing buffer. Twenty millilitres of the calibrator RD5-24 were diluted in 80 mL of deionised water to prepare 100 mL solution. The coloured reagents A and B were mixed in equal volumes 15 minutes before use and protected from light. The lipocalin-2 standard was reconstituted with 1 mL of deionised water and incubated for 15 minutes at room temperature. Subsequently, 100 μL of the standard and 900 μL were used for the standard curve. Samples and standards were performed in triplicate.

We used the software *elisaanalysis.com* to perform the analysis and curve adjustment with four logistic parameters. W obtained *r*^2^ = 0.9967093.

Statistical methods
===================

Continuous variables are expressed as the mean (± standard deviation) or median (interquartile range 25%--75%). Categorical variables are expressed as proportions. To compare patients with and without AKI, we performed Student's *t*-test or Mann-Whitney *U* test for continuous variables, as appropriate, and X^2^ test was employed for categorical variables. We constructed receiver operating characteristic (ROC) curves to estimate the sensitivity and specificity of NGAL to predict AKI within 72 hours. We performed a logistic regression analysis to determine risks factors associated with AKI, as defined by KDIGO during hospitalisation (expressed as odds ratio and 95% confidence interval: OR, 95% CI). We constructed a univariate Cox-regression analysis to assess factors related to time to death (expressed as hazard ratio: HR). Variables with *p* values \<0.05 were included in multivariate analysis.

Results
=======

Acute kidney injury
-------------------

We included 96 critically ill cancer patients. Specifically, 60 patients (63%) developed AKI and 33 (55%) were classified as stages 2 and 3. None of these patients required RRT. Comparison of general characteristics between patients with AKI and patients without AKI is presented in [Table 1](#table1){ref-type="table"}.

In total, 28 patients already had AKI at ICU admission and 32 developed AKI during their ICU stay. From the 68 patients without AKI at admission, 32 (47%) developed AKI: 19 (28%) were stage 1 patients, 10 (15%) were stage 2 patients and 3 (4%) were stage 3 patients.

In 68 patients without AKI at admission, plasma NGAL levels exhibited an AUC = 0.522 (95% CI: 0.383--0.661, *p* = 0.759) for all AKI stages, with an 81.3% sensitivity and 69.5% specificity for a 45.4 ng/mL cutoff. We observed an AUC = 0.573 (95% CI: 0.416--0.731, *p* = 0.413) for stages 2 and 3 AKI with an 84.6% sensitivity and 67.3% specificity for a 50.66 ng/mL cutoff ([Figure 2](#figure2){ref-type="fig"}).

The OR of AKI decreases depending on the increase in haemoglobin level, therefore, we constructed a ROC curve to identify the haemoglobin threshold related to a lesser AKI risk, resulting in ≥ 8.8 g/dL. Then, we categorised patients into two groups and observed that patients with haemoglobin level ≥ 8.8 g/dL had decreased risk of AKI (OR 0.138, 95% CI: 0.036--0.521, *p* = 0.004).

We identified the SOFA score (without renal parameters) at admission as an independent factor (OR 1.30, 95% CI: 1.00--1.68, *p* = 0.049) for developing stages 2 and 3 AKI. Male gender exhibited a trend towards significance (OR 4.6, 95% CI: 0.94--22.12, *p* = 0.06), and haemoglobin appeared as a protective factor (OR 0.76, 95% CI: 0.42--0.94, *p* = 0.026) ([Table 2](#table2){ref-type="table"}).

We assessed variables for collinearity and interactions and constructed a multivariate model. The AUC of the model was 0.892 (95% CI: 0.807--0.978, *p* = 0.000) for predict stages 2 and 3 AKI and the *p*-value for Hosmer-Lemeshow test was 0.822.

Factors associated with 6-month mortality
-----------------------------------------

We included 96 patients in mortality analysis ([Table 3](#table3){ref-type="table"}). We founded that age (HR 1.03, 95% CI: 1.00--1.05, *p* = 0.043), metastatic disease (HR 4.04, 95% CI: 1.45--11.29, *p* = 0.008), dobutamine use (HR 21.92, 95% CI: 3.68--130.5, *p* = 0.001), lactate at admission (HR 1.03, 95% CI: 1.01--1.05, *p* = 0.003) and stage 3 AKI (HR 2.83, 95% CI: 1.07--7.48, *p* = 0.036) were independent factors for 6-month mortality. In multivariate analysis, we observed that NGAL measured at 48 hours of admission had an HR = 1.047 (95% CI: 0.993--1.104, *p* = 0.087) for each 10 ng/mL that was not statistically significant to statistical significance to predict 6-month mortality.

The value of haemoglobin at the time of ICU admission demonstrated statistical significance as a protective factor for mortality (HR 0.81, 95% CI: 0.66--0.99, *p* = 0.047).

Discussion
==========

During the recruitment period, we observed an AKI prevalence of 63%, corresponding with other studies in critically ill oncology patients using definitions such as AKIN and KDIGO \[[@ref2], [@ref3]\].

In our group of cancer patients without AKI at the time of admission to the ICU, plasma NGAL displayed a low diagnostic performance with an AUC of 0.522 for all AKI stages. Plasma NGAL also predicted moderate to severe AKI with an AUC of 0.573 for stages 2 and 3. This finding is consistent with various previous studies in critically ill adult patients, in whom the diagnostic performance of NGAL is more variable compared with paediatric patients \[[@ref5], [@ref14]\] and adult patients exposed to contrast media or cardiac surgery \[[@ref15]\].

Studies designed to assess the diagnostic performance of NGAL to predict AKI in critically ill patients have revealed a low AUC ranging from 0.44 to 0.7 for plasma NGAL \[[@ref6], [@ref7], [@ref16]\] and values from 0.5 to 0.8 for urinary NGAL \[[@ref7], [@ref16]--[@ref18]\].

Generally, these studies compared the diagnostic accuracy of biomarkers with SCr level and did not employ precise methods, such as renal scintigraphy, to verify the reduction in glomerular filtration \[[@ref15]\]. The results can be conflicting in ICU patients, given that hypercatabolism, malnutrition, fluid overload and drugs that affect tubular excretion can modify SCr \[[@ref19], [@ref20]\].

On the other hand, biomarkers utility depends on sample timing after renal insult. However, in ICU patients, AKI is frequently multifactorial and it is not possible to determine the exact moment of the renal insult \[[@ref21]\].

Moreover, the burden of comorbidities, such as cardiovascular and renal disease may be the cause of the reported difference in NGAL performance between adults and children \[[@ref18]\]. Additionally, oncology patients possess factors that could alter NGAL expressions, such as exposure to chronic inflammation and anti-neoplastic drugs that accumulate in the renal cortex and predispose to kidney damage before acute insult \[[@ref22], [@ref23]\].

Recently, novel biomarkers of kidney injury have shown promising results to predict AKI but these biomarkers are prone to fail in a heterogeneous population of adult patients. Therefore, it is necessary to use predictive models that consider epidemiological and clinical factors \[[@ref24], [@ref25]\]. We found that SOFA score at admission may be useful for predicting the development of AKI and that haemoglobin level is a protective factor. This finding is consistent with previous studies demonstrating that AKI in critically ill cancer patients is associated with multiple organ failures \[[@ref26]\], and anaemia is a risk factor for AKI in general ICU patients \[[@ref24]\].

Han *et al* \[[@ref27]\] previously demonstrated that anaemia defined by haemoglobin \< 10.5 g/dL is an independent risk factor for AKI and mortality in a large cohort of critically ill patients, including less than 18% with neoplastic disease. In our population, we observed a mean haemoglobin level of 9.6 g/dL and a threshold of 8.8 g/dL as a risk factor for AKI. This lower haemoglobin level could be related to cytopenia in oncology patients.

Critically ill patients are exposed to hypoperfusion, and the presence of anaemia decreases the delivery of oxygen to tissues, including renal parenchyma, which normally receives 20%--25% of cardiac output. Additionally, we observed that a higher level of haemoglobin relates to lower mortality rates. The relation between anaemia and mortality occurs because anaemia can aggravate organic dysfunctions \[[@ref27]\].

In a six-month mortality analysis, we identified independent factors, such as age, metastatic disease, and severe AKI, previously described in this group of patients \[[@ref28], [@ref29]\]. We also identified that the use of dobutamine was statistically significant. One possible explanation is that almost one-third of our patients were septic, and actual guidelines for sepsis management suggest the use of dobutamine in the presence of myocardial dysfunction manifested by elevated cardiac filling pressures, low cardiac output, and signs of hypoperfusion, which may reflect illness severity. However, dobutamine increases cardiac output and splanchnic blood flow. In addition, dobutamine has not demonstrated a benefit in mortality and could even decrease survival \[[@ref30], [@ref31]\].

Based on the inclusion of SOFA score and haemoglobin in a risk model without considering renal biomarkers, we identified an AUC = 0.892. Although we obtained this result in a small cohort of patients, these findings can be useful in the construction of future models in critically ill cancer patients, for further validation in larger cohorts. We observed that NGAL measured at 48 hours of admission had an HR = 1.047 (95% CI: 0.993−1.104 for each 10 ng/mL, *p*-value = 0.087) that was not statistically significant to predict 6-month mortality. Increased NGAL levels at 48 hours could be a manifestation of the persistence of inflammation independent of kidney function \[[@ref32]--[@ref34]\].

Our study has several limitations, such as the number of patients, the heterogeneity of the population and the inability to determine the precise moment at which the renal insult occurred in a cohort of medical and surgical critically ill patients. However, most studies about renal biomarkers in cancer patients evaluate their ability to predict AKI in haemodynamically stable patients who receive nephrotoxic antineoplastic drugs. Currently, cancer patients are more frequently admitted to ICUs; therefore, exploration of the diagnostic performance of new instruments is required to improve patient care.

Conclusion
==========

In our cohort of critically ill cancer patients, NGAL did not predict AKI. SOFA score was a risk factor for developing AKI, and haemoglobin level was a protective factor for developing AKI. The independent factors associated with 6-month mortality included metastatic disease, dobutamine use, lactate and stage 3 AKI.
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Scientific knowledge on the subject
===================================

AKI is a frequent complication in ICU patients. Studies designed to analyze the ability of NGAL to predict AKI in ICU have shown variable results. Oncological patients exhibit factors that can alter the expression of NGAL. However, studies of biomarkers in oncological patients mostly include haemodynamically stable patients exposed to cytotoxic agents.

What this study adds to the field
=================================

This study demonstrates that in critically ill cancer patients the plasma NGAL was not a good predictor of AKI. We identified SOFA score at admission as a risk factor and haemoglobin level as a protective factor for developing AKI.
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###### Clinical characteristics of patients on admission to the ICU.

  Variable                                                  No AKI (*n* = 36)   AKI (*n* = 60)           *P* value
  --------------------------------------------------------- ------------------- ------------------------ -----------------------------------------------
  Male gender, *n* (%)                                      14 (38.9)           27 (45)                  0.558
  Age, mean (±SD)                                           45 (16)             50 (15)                  0.159
  Oncologic disease                                                                                      
  Haematologic malignancy, *n* (%)                          6 (17)              23 (38)                  0.025[\*](#table1_fn1){ref-type="table-fn"}
  Solid tumour *n* (%)                                      30 (83)             37 (62)                  
  Previous chemotherapy, *n* (%)                            22 (61)             39 (65)                  0.720
  Metastatic disease, *n* (%)                               16 (44)             21 (35)                  0.357
  ECOG, median (Q1, Q3)                                     1 (1−2)             1 (1−2)                  0.847
  Comorbidities                                                                                          
  Type 2 diabetes mellitus, *n* (%)                         3 (8)               14 (23)                  0.062^†^
  Systemic hypertension, *n* (%)                            4 (11)              18 (30)                  0.033[\*](#table1_fn1){ref-type="table-fn"}
  Human Immunodeficiency Virus infection, *n* (%)           0 (0)               2 (3)                    0.268
  ICU admission characteristics                                                                          
  Postoperative care, *n* (%)                               25 (69)             21 (35)                  0.001[\*](#table1_fn1){ref-type="table-fn"}
  APACHE II score, median (Q1, Q3)                          13 (8−16)           15 (12−21)               0.005[\*](#table1_fn1){ref-type="table-fn"}
  SOFA score, median (Q1, Q3)                               4 (2−7)             7 (4−9)                  0.004[\*](#table1_fn1){ref-type="table-fn"}
  Mechanical ventilation, *n* (%)                           19 (53)             37 (62)                  0.392
  Sepsis, *n* (%)                                           6 (17)              23 (38)                  0.025[\*](#table1_fn1){ref-type="table-fn"}
  Norepinephrine, *n* (%)                                   14 (39)             40 (67)                  0.008[\*](#table1_fn1){ref-type="table-fn"}
  Dobutamine, *n* (%)                                       0 (0)               3 (5)                    0.289
  Cardiac arrhythmias, *n* (%)                              0 (0)               6 (10)                   0.050^†^
  Sodium, median (Q1, Q3), (mEq/L)                          138 (134−141)       138 (135−140)            0.914
  Potassium, median (Q1, Q3), (mEq/L)                       3.8 (3.4−4.1)       3.9 (3.4−4.8)            0.173
  Haemoglobin, mean (±SD), (g/dL)                           10.2 (2.45)         9.3 (2.38)               0.065^†^
  Leucocytes, median (Q1, Q3), (×10^9^/L)                   10.6 (5−13.6)       7.1 (1.2−14.7)           0.264
  Neutrophils, median (Q1, Q3), (×10^9^/L)                  9.5 (4.6−12.3)      6.1 (1.6−13.2)           0.292
  Platelets, median (Q1, Q3), 10^9^/L                       151 (105−231)       176 (57−227)             0.588
  Bilirubin, median (Q1, Q3), (mg/dL)                       0.9 (0.65−1.83)     0.8 (0.5−1.3)            0.193
  pH, median (Q1, Q3)                                       7.33 (7.28−7.41)    7.38 (7.26−7.43)         0.375
  Lactate, median (Q1, Q3), (mmol/L)                        2.1 (1.6−3.3)       2.5 (1.6−4.7)            0.366
  Renal function                                                                                         
  Basal creatinine, mean (±SD), (mg/dL)                     0.75 (0.17)         0.73 (0.19)              0.743
  Basal CKD-EPI, mean (±SD)                                 104 (21)            101 (20)                 0.512
  Creatinine at ICU admission, median (Q1, Q3), (mg/dL)     0.67 (0.58−0.76)    0.93 (0.67−1.4)          \<0.001[\*](#table1_fn1){ref-type="table-fn"}
  BUN at admission, median (Q1, Q3), (mg/dL)                10.7 (6.9−17.3)     17 (11.1−24.5)           0.003[\*](#table1_fn1){ref-type="table-fn"}
  NGAL at admission, median (Q1, Q3), (ng/mL)               95.8 (28−196.8)     77.5 (45.5−138.1)        0.931
  NGAL at 48 hours, median (Q1, Q3), (ng/mL)                65.9 (26.9−109.8)   85.9 (34.5−126.6)        0.258
  Delta NGAL, median (Q1, Q3), (ng/mL)                      −19.6 (−78 to +5)   −11.1 (−39.8 to +14.4)   0.102
  Outcomes                                                                                               
  Length of mechanical ventilation, median (Q1, Q3), days   1 (0−5)             1 (0−5)                  0.373
  Days with norepinephrine, median (Q1, Q3)                 0 (0−2)             2 (0−3)                  0.026[\*](#table1_fn1){ref-type="table-fn"}
  Length of stay in ICU, median (Q1, Q3), days              2 (1−4)             3 (1−5)                  0.198
  Death at ICU, *n* (%)                                     5 (14)              7 (12)                   0.750
  Death at 180 days, (%)                                    6 (17)              27 (45)                  0.005[\*](#table1_fn1){ref-type="table-fn"}

*p* value \< 0.05 trend towards significance.

AKI: Acute kidney injury, ECOG: Eastern Cooperative

Oncology Group, ICU: intensive care unit, APACHE: Acute physiology and chronic health evaluation, SOFA: Sequential organ failure assessment, CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration, BUN: Blood urea nitrogen, NGAL: neutrophil gelatinase-associated lipocalin.

###### Factors associated with AKI.

  Variable                  Bivariate analysis   Multivariate analysis                                                                       
  ------------------------- -------------------- ----------------------- --------------------------------------------- ------- ------------- ---------------------------------------------
  Age                       1.019                0.982−1.058             0.315                                         1.035   0.988−1.083   0.146
  Male gender               3.937                1.073−14.44             0.039[\*](#table2_fn1){ref-type="table-fn"}   4.552   0.937−22.12   0.060
  Haematologic malignancy   4.667                1.304−16.70             0.018[\*](#table2_fn1){ref-type="table-fn"}   0.764   0.112−5.209   0.783
  Haemoglobin               0.640                0.470−0.873             0.005[\*](#table2_fn1){ref-type="table-fn"}   0.626   0.415−0.944   0.026[\*](#table2_fn1){ref-type="table-fn"}
  SOFA score                1.305                1.068−1.594             0.009[\*](#table2_fn1){ref-type="table-fn"}   1.296   1.001−1.678   0.049[\*](#table2_fn1){ref-type="table-fn"}

*p* value \< 0.05, SOFA: Sequential organ failure assessment.

###### Cox proportional hazards analyses of factors associated with increased 6-month mortality rate.

  Variable                                 Bivariate analysis   Multivariate analysis                                                                       
  ---------------------------------------- -------------------- ----------------------- --------------------------------------------- ------- ------------- ---------------------------------------------
  Age                                      1.017                0.994−1.040             0.151                                         1.025   1.001−1.050   0.043[\*](#table3_fn1){ref-type="table-fn"}
  Male gender                              1.017                0.994−1.040             0.151                                         0.763   0.356−1.635   0.487
  Postoperative care                       0.470                0.218−1.013             0.054                                         0.657   0.254−1.701   0.387
  Metastatic disease                       2.280                1.083−4.802             0.030[\*](#table3_fn1){ref-type="table-fn"}   4.044   1.448−11.29   0.008[\*](#table3_fn1){ref-type="table-fn"}
  Human Immunodeficiency Virus infection   5.189                1.164−23.13             0.031[\*](#table3_fn1){ref-type="table-fn"}   4.857   0.797−29.62   0.087
  Dobutamine                               8.079                1.736−37.61             0.008[\*](#table3_fn1){ref-type="table-fn"}   21.92   3.682−130.5   0.001[\*](#table3_fn1){ref-type="table-fn"}
  Haemoglobin                              0.883                0.764−1.021             0.093                                         0.809   0.657−0.997   0.047[\*](#table3_fn1){ref-type="table-fn"}
  Total neutrophils                        0.944                0.888−1.004             0.067                                         0.973   0.920−1.029   0.337
  Lactate at ICU admission                 1.024                1.010−1.038             0.001[\*](#table3_fn1){ref-type="table-fn"}   1.028   1.010−1.046   0.003[\*](#table3_fn1){ref-type="table-fn"}
  NGAL at 48 hours (for each 10 ng/mL)     1.046                1.000−1.097             0.061                                         1.047   0.999−1.104   0.087
  KDIGO stage 3                            3.520                1.129−10.98             0.030[\*](#table3_fn1){ref-type="table-fn"}   2.828   1.069−7.480   0.036[\*](#table3_fn1){ref-type="table-fn"}

*p* value \<0.05.

ICU: intensive care unit, NGAL: neutrophil gelatinase-associated lipocalin, KDIGO: Kidney Disease: Improving Global Outcomes.
